We've sent out a couple tweets from @celltherapyblog this week that we have now tracked over $1 billion having been brought in by companies in the cell therapy and cell-based regenerative medicine space this year to-date.
We promise to post a breakdown of this stat updating our most recent post on the subject back in July but we want to wait until the month ends and we see a number of pending financings close.
We're closing the week with a Fibrocell Sciences ($FCSC) PIPE that was supposed to close Oct 11, an Immunocellular Therapeutics ($IMUC) secondary offering that supposed to close Oct 23, and an Athersys ($ATHX) secondary offering that aims to close by Halloween.
Watch for more details the first full week of November.
No comments:
Post a Comment